Porcine circovirus type 2 or type 3 virus-like particle as well as preparation method and application thereof
By optimizing the pig cyclovirus Cap protein sequence and insect expression system, the problems of complex purification and low preparation efficiency of virus-like particles in the prior art are solved, and efficient preparation of pig cyclovirus type 2 and type 3 virus-like particles vaccines are achieved. Significantly improves immune effects and is suitable for mass production.
Patent Information
- Application Number
- CN202411043988.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-15
AI Technical Summary
The preparation method of existing pig circovirus-related virus-like particle vaccines has the problem of complex purification process and low preparation efficiency. Especially for PCV3 vaccines, the existing PCV2 vaccine does not provide specific protection for its infection, resulting in a lack of Commercial vaccine.
By optimizing the cyclovirus type 2 and 3 Cap protein sequences of pig cyclovirus, combining with insect expression systems for recombinant expression and purification, efficient virus-like particles were obtained by cation exchange chromatography and other methods, and prepared as bivalent virus-like particle vaccine.
It improves the preparation efficiency of PCV2 and PCV3 antigens, forms significant immune effects, the purification process is simple and easy to operate, suitable for large-scale production, and provides effective immune protection against PCV3.
Smart Images

Figure CN118955650A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biopharmaceutical technology, and in particular to porcine circovirus type 2 or type 3 virus-like particles and their application in vaccine preparation. Background Art
[0002] Porcine circovirus (PCV) is a single-stranded circular DNA virus belonging to the Circoviridae family and the Circovirus genus. The virus particle diameter is 17-25nm. Porcine circovirus has been prevalent in the current pig herd for a long time, causing huge losses to the pig farming industry. There are currently three recognized serotypes of porcine circovirus, namely porcine circovirus type 1, type 2 and type 3.
[0003] PCV1 was first isolated from a porcine kidney cell line in 1974, but has not been found to be associated with clinical diseases in pigs and is considered to be non-pathogenic. PCV2 is one of the main pathogens that causes major economic losses in the pig industry and is currently the most intensively studied porcine circovirus. It is associated with a variety of clinical diseases, such as post-weaning multisystemic wasting syndrome (PMWS), porcine dermatitis and nephropathy syndrome (PDNS), and proliferative necrotizing pneumonia. It is also associated with reproductive disorders in sows, congenital tremor in piglets, and immunosuppression. PCV2 mainly replicates in the lymphoid tissues, alveolar macrophages, and peripheral blood mononuclear cells of pigs, and is mainly transmitted through direct contact, aerosol fecal-oral route, and vertical transmission. Vaccines against PCV2 have been commercialized and widely used, including whole virus inactivated vaccines and subunit vaccines. PCV3 is a new type first discovered in pigs in the United States in 2016, and has subsequently been reported around the world. PCV3 also replicates in the lymphoid tissue and immune cells of pigs and is considered a potential pathogen that causes reproductive disorders, dermatitis nephropathy syndrome, and myocarditis in pigs. PCV3 has significant differences in both nucleotide and amino acid sequences compared to PCV2. The total nucleotide sequence similarity of the two genomes is less than 50%, and the similarity of the main capsid protein amino acid sequence is less than 30%. According to literature reports, the existing PCV2 vaccine does not provide specific protection against PCV3 infection, so there is currently no commercial PCV3 vaccine available.
[0004] Virus-like particles (VLPs) are nanoscale hollow particles that are self-assembled from one or more viral structural proteins and have similar morphology and structural characteristics to viruses, but do not contain viral genetic material. In short, VLPs are non-infectious pseudoviruses that can trigger a strong immune response from the immune system. Therefore, VLP vaccines are both safe and highly effective, and have important application value in vaccine development and biotechnology.
[0005] The currently disclosed methods for preparing porcine circovirus-related virus-like particle vaccines have problems such as complex virus-like particle purification process and low preparation efficiency.
[0006] In view of this, the present invention is proposed. Summary of the invention
[0007] The object of the present invention is to provide a porcine circovirus type 2 or type 3 virus-like particle and its application in the preparation of a vaccine. The preparation method of the porcine circovirus type 2 or type 3 virus-like particle of the present invention can improve the preparation efficiency of the virus-like particle, so that it maintains the VLP form and also has a good immune effect.
[0008] The present invention is achieved in that:
[0009] In the first aspect, the present invention provides a porcine circovirus type 2 or type 3 virus-like particle, including porcine circovirus type 2 virus-like particles and porcine circovirus type 3 virus-like particles; porcine circovirus type 2 virus-like particles include porcine circovirus type 2 Cap protein, and porcine circovirus type 3 virus-like particles include porcine circovirus type 3 Cap protein; the nucleotide sequence of the porcine circovirus type 2 Cap protein gene is shown in SEQ ID NO.2, and the nucleotide sequence of the porcine circovirus type 3 Cap protein gene is shown in SEQID NO.4.
[0010] In a second aspect, the present invention provides a method for preparing the above-mentioned porcine circovirus type 2 or type 3 virus-like particles, which comprises: connecting a nucleic acid molecule encoding porcine circovirus type 2 Cap protein to a shuttle plasmid, and then transforming the obtained recombinant vector into a host competent cell to form a recombinant bacmid comprising the nucleic acid molecule of claim 1, and then transfecting the recombinant bacmid into insect cells to obtain recombinant cells; fermenting and culturing the recombinant cells, and isolating and purifying them to obtain porcine circovirus type 2 virus-like particles and porcine circovirus type 3 virus-like particles.
[0011] In a third aspect, the present invention also provides a porcine circovirus type 2 / type 3 bivalent virus-like particle vaccine, which includes the above-mentioned porcine circovirus type 2 virus-like particles and porcine circovirus type 3 virus-like particles.
[0012] The present invention has the following beneficial effects:
[0013] The present invention obtains a novel preparation method of porcine circovirus type 2 or type 3 virus-like particles by optimizing the Cap protein sequence of porcine circovirus type 2 and type 3, as well as optimizing the expression and purification conditions. The preparation method can improve the preparation efficiency of PCV2 and PCV3 antigens, and the expressed PCV2 and PCV3 antigen proteins can form virus-like particles, and the immune effect of preparing them into bivalent virus-like particle vaccines is significant. At the same time, the purification process of the virus-like particles of the present invention is simple and easy to operate, the production cost is low, and it can be used for large-scale production. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0015] Figure 1 The results of SDS-PAGE detection (1A) and Western Blot (1B) of the PCV2d-pre and PCV2d-post expression products in Example 1, wherein lane 1: Protein marker; lane 2: PCV2d-post expression product SDS-PAGE; lane 3: PCV2d-pre expression product SDS-PAGE; lane 4: sf9 cell control; lane 5: Protein marker; lane 6: PCV2d-post expression product western blot identification; lane 7: PCV2d-pre expression product western blot identification; lane 8: sf9 cell control;
[0016] Figure 2 The results of SDS-PAGE detection of the purified sample of PCV2d-post expression product in Example 1, wherein lane 1: Protein marker; lane 2: purified sample of PCV2d-post expression product;
[0017] Figure 3 The PCV2d VLP morphology identification results in Example 1;
[0018] Figure 4 The results of SDS-PAGE detection of PCV3-pre and PCV3-post expression products in Example 1, wherein lane 1: Protein marker; lane 2: sf9 cell control; lane 3: PCV3-post expression product SDS-PAGE; lane 4: PCV3-pre expression product SDS-PAGE;
[0019] Figure 5 The results of SDS-PAGE detection of the purified sample of PCV3-post expression product in Example 1, wherein lane 1: Protein marker; lane 2: purified sample of PCV3-post expression product;
[0020] Figure 6 This is the PCV3 VLP morphology identification result in Example 1. DETAILED DESCRIPTION
[0021] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0022] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the aspects and embodiments described herein belong or relate. The following references provide those of skill in the art with general definitions of many of the terms used in the aspects and embodiments described herein: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker, ed., 1988); The Glossary of Genetics, 5th ed., R. Rieger et al. (eds.), Springer Verlag (1991); Benjamin Lewin, Genes V, published by Oxford University Press, 1994 (ISBN 0-19-854287-9); Kendrew et al. (eds.); The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); Molecular Biology and Biotechnology: a Comprehensive Desk Reference, Robert A. Meyers (ed.), published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). Unless otherwise indicated, the following terms as used herein have the meanings assigned to them below.
[0023] A "codon optimized" nucleic acid refers to a nucleic acid sequence that has been altered so that the codons are optimal for expression in a particular system, such as a particular species or group of species. For example, a nucleic acid sequence can be optimized for expression in mammalian cells. Codon optimization does not change the amino acid sequence of the encoded protein.
[0024] "Recombinant" refers to proteins, genetically engineered vectors or cells obtained (or prepared in large quantities) by means of genetic engineering.
[0025] "Vector" refers to bacterial plasmids, bacteriophages, yeast plasmids, plant cell viruses, mammalian cell viruses or other vectors well known in the art. In short, any plasmid and vector can be used as long as they can replicate and be stable in the host.
[0026] "Host cell" refers to any cell type that is susceptible to transformation, transfection, transduction, etc. with a nucleic acid construct or expression vector comprising a nucleic acid molecule of the present invention.
[0027] "Vaccine" refers to a preparation of immunogenic material (e.g., protein or nucleic acid) capable of stimulating (eliciting) an immune response, such as a protein or peptide antigen, which is administered to a subject to treat a disease, disorder or condition, or to prevent or protect against a disease, disorder or condition, such as an infectious disease, e.g., a viral infection. Immunogenic materials may include, for example, attenuated or inactivated microorganisms (e.g., attenuated viruses), or antigenic proteins, peptides, DNA or RNA derived from such microorganisms.
[0028] "Virus-like particles (VLPs)" refer to viral particles that are composed of one of a variety of viral structural proteins but lack the viral genome. Since VLPs lack the viral genome, they are not infectious and produce safer and potentially more economical vaccines and vaccine products.
[0029] "Adjuvant" refers to a substance or vehicle that non-specifically enhances the immune response to an antigen. An adjuvant may include a mineral suspension (e.g., alum, aluminum hydroxide, or phosphate) on which an antigen is adsorbed; or an oil-in-water emulsion, wherein the antigen solution is emulsified in mineral oil (e.g., Freund's incomplete adjuvant), sometimes containing inactivated mycobacteria (Freund's complete adjuvant) to further enhance antigenicity. Immunostimulatory oligonucleotides (such as those comprising CpG motifs) may also be used as adjuvants (see, e.g., U.S. Patent Nos. 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; 6,339,068; 6,406,705; and 6,429,199). Adjuvants also include biomolecules, such as costimulatory molecules. Exemplary biological adjuvants include, but are not limited to, interleukin-1 (IL-2), the protein memory T cell attractant "regulated activated normal T cell expressed and secreted factor" (RANTES), granulocyte-macrophage-colony stimulating factor (GM-CSF), tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), granulocyte colony stimulating factor (G-CSF), lymphocyte function-associated antigen 3 (LFA-3, also known as CD58), cluster differentiation antigen 72 (CD72) (a negative regulator of B cell responsiveness), peripheral membrane protein B7-1 (B7-1, also known as CD80), peripheral membrane protein B7-2 (B7-2, also known as CD86), TNF ligand superfamily member 4 ligand (OX40L) or type 2 transmembrane glycoprotein receptor belonging to the TNF superfamily (4-1BBL).
[0030] "Agent" refers to any small molecule, small molecule compound, antibody, nucleic acid molecule, peptide, polypeptide or fragment thereof.
[0031] "Antibody" refers to an immunoglobulin (Ig) molecule produced by B lymphocytes and having a specific amino acid sequence. Antibodies are induced or triggered in a subject (human or other animal or mammal) after exposure to a specific antigen (immunogen). A subject who is able to produce antibodies / immunoglobulins (i.e., an immune response) against a specific antigen / immunogen is considered to be immunocompetent. Antibodies are characterized by specifically reacting (e.g., binding) with an antigen or immunogen in some demonstrable manner, and antibodies and antigens / immunogens are each defined in relation to each other.
[0032] In the present invention, porcine circovirus includes porcine circovirus type 2 and porcine circovirus type 3, specifically, porcine circovirus type 2 is porcine circovirus type 2d. The present invention optimizes the codons of the capsid protein Cap of porcine circovirus type 2d and porcine circovirus type 3 according to the baculovirus insect expression system, and the expression amount of the capsid protein Cap is improved after optimization.
[0033] In some embodiments, the nucleotide sequence of the porcine circovirus type 2d Cap protein gene before optimization is as shown in SEQ ID NO.1:
[0034] ATGACGTATCCAAGGAGGCGTTTCCGCAGACGAAGACACCGCCCCCGCAGCCATCTTGGCCAGATCCTCCGCCGCCGCCCCTGGCTCGTCCA CCCCCGCCACCGTTACCGCTGGAGAAGGAAAAATGGCATCTTCAACACCCGCCTCTCCCGCACCATCGGTTATACTGTCAAGAAAACCACAGTCAGAACGCCCTCCTGGAATGTGGACATGATGAGATTTAATATTAATGATTTTCTTCCCCCAGGAGGGGGCTCAAACCCCCTCACTGTGCCCTTTGAATACTACAGAATAAGAAAGGTTAAGGTTGAATTCTGGCCCTGCTCCCCAATCACCCAGGGTGACAGGGGAGTGGGCTCCACTGCTGTTATTCTAGATGATAACTTTGTAACAAAGGCCAATGCCCTAACCTATGACCCCTATGTAAACTACTCCTCCCGCCATACCATAACCCAGCCCTTCTCCTACCACTCCCGGTACTTTACCCCGAAACCTGTCCTTGATAGGACAATCGATTACTTCCAACCCAATAACAAAAGAAATCAACTCTGGCTGAGACTACAAACTACTGGAAATGTAGACCATGTAGGCCTCGGCACTGCGTTCGAAAACAGTATATACGACCAGGACTACAATATCCGTATAACCATGTATGTACAATTCAGAGAATTTAATCTTAAAGACCCCCCACTTAACCCTAAGTAG。
[0035] The optimized nucleotide sequence is shown in SEQ ID NO.2:
[0036] ATGACTTATCCAAGAAGGAGATATAGAAGGAGAAGACATAGACCAAGATCTCATTTGGGTCAAATTTTGAGAAGGAGACCATGGTTGTTGCACCCAAGACATAGATACAGATGGAGAAGGAAAAATGGTATCTTTAATACTAGGTTATCTAGAACAATTGGTTACACTGT TAAAAAAACTACTGTTAGAACTCCATCTTGGAATGTTGATATGATGAGATTTAATATTAATGATTTTTTGCCACCTGGTGGAGGTTCTAATCCATTGACTGTTCCATTTGAATATTATAGAATTAGAAAAGTTAAAGTTGAATTTTGGCCATGTTCTCCAATTACTCAAG GTGATAGAGGTGTTGGTTCAACTGCTGTTATTTTGGATGACAATTTCGTTACTAAAGCTAATGCTTTGACTTATGATCCATATGTTAATTATTCTTCTAGACATACTATCACTCAGCCTTTTTCTTATCATTCTAGATATTTTACTCCAAAACCTGTTTTGGATGGTACT ATTGATTATTTTCAACCAAATAATAGAAGAAATCAATTGTGGTTGAGATTGCAAACTACTGGTAATGTTGATCATGTTGGTTTGGGAACAGCTTTTGAAAACTCTATTTATGACCAAGATTACAATATTAGGATTACAATGTATGTTCAGTTTAGAGAGTTTAATTTGAA AGATCCACCATTGAATCCAAAATAA.
[0037] In some embodiments, the nucleotide sequence of the porcine circovirus type 3 Cap protein gene before optimization is as shown in SEQ ID NO.3:
[0038] ATGAGACACAGAGCTATATTCAGAAGAAGACCCCGCCCAAGGAGACGACGACGCCACAGAAGGCGCTATGTTAGAAGAAAACTATTCATTAGGAGGCCCACAGCTGGCACATACTACACAAAGAAATACTCCACAATGAACGTCATATCCGTTGGAACCCCTCAGAATAACAAGCCCTGGCACGCCAACCACTTCATTACCCGCCTAAACGAATGGGAAACTGCAATTTCTTTTGAATATTATAAGATACTAAAAATGAAAGTTACACTCAGCCCTGTAATTTCTCCGGCTCAGCAAACAAAAACTATGTTCGGGCACACAGCCATAGATCTAGACGGCGCCTGGACCACAAACACTTGGCTCCAAGACGACCCTTATGCGGAAAGTTCCACTCGTAAAGTTATGACTTCTAAAAAAAAACACAGCCGTTACTTCACCCCCAAACCAATTCTGGCGGGAACTACCAGCGCTCACCCAGGACAAAGCCTCTTCTTTTTCTCCAGACCCACCCCATGGCTCAACACATATGACCCCACCGTTCAATGGGGAGCACTGCTTTGGAGCATTTATGTCCCGGAAAAAACTGGAATGACAGACTTCTACGGCACCAAAGAAGTTTGGATTCGTTACAAGTCCGTTCTCTAA。
[0039] The optimized nucleotide sequence is shown in SEQ ID NO.4:
[0040] ATGAGACATAGAGCTATTTTTAGAAGGAGACCAAGACCAAGAAGGAGAAGGAGACATAGAAGGAGATATGTTAGAAGAAAATTGTTTATTAGAAGACCAACTGCTGGTACTTATTATACTAAAAAGTACTCTACTATGAATGTTATTTCTGTTGGTACTCCACAAAATAATAAACCATGGCATGCAAATCATTTTATTACTAGATTAAACGAATGGGAAACAGCAATTTCTTTCGAATACTA TAAGATTCTTAAAAAATGAAAGTTACTTTGTCTCCTGTTATTTCTCCTGCTCAACAAACTAAAACTATGTTTGGTCATACTGCTATTGATTTGGATGGTGCTTGGACTACTAATACTTGGTTGCAAGATGATCCATATGCTGAATCTTCTACTAGAAAAGTTATGACTTCTAAGAAAAAACATTCTAGATATTTTACTCCAAAACCAATTTTGGCTGGTACTACTTCTGCTCATCCTGGTCAAT CTTTGTTTTTCTTTTCTAGACCAACTCCATGGTTGAATACTTATGATCCAACTGTTCAATGGGGTGCTTTGTTGTGGTCTATTTATGTTCCTGAAAAAAACTGGTATGACTGATTTTTATGGTACTAAAGAAGTTTTGGATTAGATATAAATCTGTTTTGTAA.
[0041] According to the above nucleic acid molecules, an expression cassette combination can be obtained, and the expression cassette in the combination can be an expression cassette containing the nucleotide sequence of the porcine circovirus type 2d Cap protein, or an expression cassette containing the nucleotide sequence of the porcine circovirus type 3 Cap protein, or an expression cassette containing the nucleotide sequence of the porcine circovirus type 2d and type 3 Cap proteins. At the same time, the expression cassette also contains regulatory sequences, such as promoters and terminators.
[0042] A recombinant vector can be obtained according to the above nucleic acid molecule or expression cassette, and the recombinant vector comprises the above nucleic acid molecule or expression cassette combination.
[0043] According to the above nucleic acid molecule, expression cassette or recombinant vector, a recombinant cell can also be obtained, and the recombinant cell comprises the above nucleic acid molecule, expression cassette or recombinant vector.
[0044] A new porcine circovirus type 2 or type 3 virus-like particle can be prepared using the above-mentioned biological material. The method includes: connecting the optimized nucleic acid molecule to a shuttle plasmid, then transforming the obtained recombinant vector into a host competent cell to form a recombinant bacmid containing the above-mentioned optimized nucleic acid molecule, and then transfecting the recombinant bacmid into insect cells to obtain a recombinant cell; fermenting and culturing the recombinant cell, separating and purifying the recombinant cell to obtain porcine circovirus type 2d antigen and porcine circovirus type 3 antigen, namely, porcine circovirus type 2d virus-like particle and porcine circovirus type 3 virus-like particle.
[0045] In some embodiments, the shuttle plasmids include pFastBac HTA, pFastBac HTB, pFastBacHTC, pFastBac 1 and pFastBac Dual.
[0046] In some embodiments, the insect cells include sf9 cells and High Five cells.
[0047] In some embodiments, the purification comprises: subjecting the lysed supernatant to cation exchange chromatography.
[0048] In some embodiments, the fillers of the cation exchange chromatography include SP LS HP and Capto S ImpAct fillers. Specifically, the filler used in the cation exchange chromatography of porcine circovirus type 2d virus-like particles is SP LS HP (Lanxiao), and the filler used in the cation exchange chromatography of porcine circovirus type 3 virus-like particles is Capto S ImpAct (cytiva).
[0049] In some embodiments, the eluent of the cation exchange chromatography is: 20mM PB, 1M NaCl, pH = 6.8; or the eluent is: 20mM PB, 200mM NaCl, pH = 6.8. Specifically, the eluent used in the cation exchange chromatography of porcine circovirus type 2d virus-like particles is: 20mM PB, 1M NaCl, pH = 6.8; the eluent used in the cation exchange chromatography of porcine circovirus type 3 virus-like particles is: 20mM PB, 200mM NaCl, pH = 6.8.
[0050] In some embodiments, the method for obtaining the supernatant is: adding buffer to the recombinant cells expressing porcine circovirus type 2d and type 3 Cap proteins to resuspend them, breaking the recombinant cells after mixing, and obtaining the supernatant after centrifugation.
[0051] In some embodiments, the buffer is: 20mM PB, 100mM NaCl, pH = 6.8, or the buffer is: 20mMPB, 10mM NaCl, pH = 6.8. Specifically, the buffer used for the supernatant of porcine circovirus type 2d is: 20mM PB, 100mM NaCl, pH = 6.8; the buffer used for the supernatant of porcine circovirus type 3 is: 20mM PB, 10mM NaCl, pH = 6.8.
[0052] After screening tests, it was found that the above-mentioned fillers and eluents are more suitable for the purification of porcine circovirus type 2 or type 3 virus-like particles, and the use of the above-mentioned fillers and eluents can achieve better separation and purification effects.
[0053] The porcine circovirus type 2 or type 3 antigens obtained by the above preparation method have a higher expression level and can form virus-like particles. The above virus-like particles can be used to prepare a porcine circovirus type 2 / type 3 bivalent virus-like particle vaccine, and the preparation method is as follows:
[0054] The purified porcine circovirus type 2 or type 3 antigen was sterilized by filtering with a 0.22 μm filter membrane, and then the two antigens were adjusted to 120 μg / mL, respectively, and then mixed at a volume ratio of 1:1 to 1:2. The resulting mixture was then mixed with the adjuvant at a volume ratio of 9:1 to 1:1 and emulsified to obtain a porcine circovirus type 2 / 3 bivalent virus-like particle vaccine.
[0055] Experiments have shown that the porcine circovirus type 2 / type 3 bivalent virus-like particle vaccine prepared by the present invention can obtain good immune protection.
[0056] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0057] Example 1
[0058] This embodiment is a method for preparing porcine circovirus type 2 and type 3 virus-like particles, comprising:
[0059] 1. Construction of recombinant bacmid containing PCV2d Cap gene. The specific steps are as follows:
[0060] S1. An optimized Cap gene sequence is provided for the recombinant expression of the major capsid protein Cap of porcine circovirus type 2d in an insect-baculovirus expression system. The genes before and after optimization are named PCV2d-pre and PCV2d-post, respectively (as shown in SEQ ID NO.1-2).
[0061] S2. The genes before and after codon optimization were obtained by gene synthesis, and the genes containing Rsr II and Hind III restriction sites were cloned into the pFastBac HTB vector to obtain two recombinant shuttle plasmids pFastBac-PCV2d-pre and pFastBac-PCV2d-post. After sequencing detection, both genes were accurately inserted into the corresponding positions of the vector.
[0062] S3. The two were transformed into DH10Bac competent cells respectively, and two recombinant bacmids Bacmid-PCV2d-pre and Bacmid-PCV2d-post were obtained through blue-white screening.
[0063] 2. Construction and propagation of PCV2d recombinant baculovirus
[0064] According to the liposome transfection method described in the Thermo Fisher manual "Bac-to-Bac Baculovirus Expression System", the two recombinant bacmids Bacmid-PCV2d-pre and Bacmid-PCV2d-post were transfected into sf9 insect cells. The cell supernatant was harvested 5 days later, which was the P1 generation virus. It was blindly propagated to the P3 generation in a 6-well plate. The P3 generation recombinant virus was inoculated at a density of 1E6 / mL in sf9 suspension cells at 1:500. The cell supernatant was collected 4 days later, which was the P4 generation virus.
[0065] 3. Expression and identification of recombinant proteins
[0066] The P4 recombinant viruses of the two strains were inoculated into sf9 cells with a density of 2E6 cells / mL at a dose of MOI 0.1. The cell viability was measured every 24 hours. When the cell viability dropped below 50%, the cells were harvested by centrifugation at 8000 rpm for 10 minutes.
[0067] The same amount of sample was used for SDS-PAGE detection. Figure 1 The detection results of A show that the gene expression products before and after optimization showed specific bands at around 28kD, and the expression level of the optimized gene was higher and the impurity protein was less.
[0068] Western Blot was performed using PCV2 swine high immune serum (China Veterinary Drug Administration) as the primary antibody. Figure 1 The identification results of B showed that the negative control had no specific band at 28kD, while the PCV2d-pre and PCV2d-post expression products both showed specific bands at 28kD, which was in line with expectations.
[0069] 4. Purification of PCV2d Cap recombinant protein
[0070] S1. Prepare Buffer A (20mM PB, 100mM NaCl, pH6.8) as the buffer for disrupting cells, which is also the equilibrium buffer in the ion exchange process; Buffer B (20mM PB, 1M NaCl, pH6.8) is the elution buffer and is set aside.
[0071] S2. Take 10 g of frozen cell sample expressing PCV2d-post, add 100 mL of Buffer A to resuspend, stir evenly, and then use a high-pressure cell crusher to crush twice at a pressure of 500 bar, centrifuge at 10,000 rpm for 30 min, and collect the supernatant.
[0072] S3. The supernatant was subjected to cation exchange chromatography using SP LS HP filler (Lanxiao Biotechnology) and eluted using Buffer B.
[0073] Depend on Figure 2 The SDS-PAGE results showed that the target protein accounted for more than 70% after purification, indicating that one-step cationic purification can effectively remove impurity proteins.
[0074] 5. PCV2d VLP morphology identification
[0075] The purified samples were negatively stained with phosphotungstic acid solution and observed using a transmission electron microscope.
[0076] like Figure 3 The results showed that a large number of spherical particles with a diameter of about 20 nm were visible in the solution, indicating that the purified PCV2dCap recombinant protein existed in the form of VLP.
[0077] 6. Construction of Bacmid-PCV3 recombinant bacmid
[0078] S1. The original PCV3 Cap gene was optimized by utilizing the codon preference of insect cells, and the genes before and after codon optimization were obtained by gene synthesis, which were named PCV3-pre and PCV3-post, respectively (as shown in SEQ ID NO.3-4).
[0079] S2. The two genes containing Rsr II and Hind III restriction sites were cloned into the pFastBac HTB vector respectively to obtain two recombinant shuttle plasmids pFastBac-PCV3-pre and pFastBac-PCV3-post. The two plasmids were transformed into DH10Bac competent cells and the recombinant bacmids Bacmid-PCV3-pre and Bacmid-PCV3-post were obtained through blue-white spot screening.
[0080] 7. Construction and propagation of PCV3 recombinant baculovirus
[0081] According to the liposome transfection method described in the manual "Bac-to-Bac Baculovirus Expression System" of Thermo Fisher, the two recombinant bacmids Bacmid-PCV3-pre and Bacmid-PCV3-post were transfected into sf9 insect cells respectively. After 5 days, the cell supernatant was harvested, which was the P1 generation virus. It was blindly propagated to the P3 generation in a 6-well plate. The P3 generation recombinant virus was inoculated at a density of 1E6 / mL in sf9 suspension cells at 1:500. After 4 days, the cell supernatant was collected, which was the P4 generation virus.
[0082] 8. Expression of PCV3 Cap recombinant protein
[0083] The two P4 recombinant viruses were inoculated into sf9 cells with a density of 2E6 cells / mL at a dose of MOI 0.1, and the cell viability was measured every 24 hours. When the cell viability dropped below 50%, the cells were harvested by centrifugation at 8000 rpm for 10 minutes and identified by SDS-PAGE.
[0084] like Figure 4 The identification results showed that compared with the control cells, the two recombinant expression samples PCV3-post and PCV3-pre both showed specific bands at 27kD, which was consistent with the molecular weight of PCV3 Cap. Moreover, the recombinant protein expression of the PCV3-post gene was much higher than that of the unoptimized gene PCV3-pre.
[0085] 9. Purification of PCV3 Cap recombinant protein
[0086] S1. Prepare Buffer C (20mM PB, 10mM NaCl, pH6.8) as the buffer for disrupting cells, which is also the equilibrium buffer in the ion exchange process; Buffer D (20mM PB, 200mM NaCl, pH6.8) is the elution buffer and is set aside.
[0087] S2. Take 10 g of frozen PCV3-post gene-expressing cell sample, add 100 mL of Buffer C to resuspend, stir evenly, and then use a high-pressure cell crusher to crush twice at a pressure of 500 bar, centrifuge at 10,000 rpm for 30 min, and collect the supernatant.
[0088] S3. The supernatant was collected and used as the loading solution for ion exchange purification. Capto S ImpAct (cytiva) was used as the medium for cation exchange chromatography, and Buffer D was used as the eluent for elution.
[0089] like Figure 5The results showed that Capto S ImpAct cation exchange can effectively purify PCV3Cap protein.
[0090] 10. PCV3 VLP morphology identification
[0091] The purified PCV3 VLP samples were negatively stained and observed using a transmission electron microscope.
[0092] Figure 6 A large number of spherical VLP particles with a diameter of about 20 nm can be observed, which is similar to the size of natural PCV3 virus particles.
[0093] Example 2
[0094] This example is the preparation of a bivalent porcine circovirus VLP vaccine, as follows:
[0095] The two purified VLP antigens were sterilized by filtering with a 0.22 μm filter membrane and then quantified by the BCA method. According to the quantitative results, the two antigens were adjusted to 120 μg / mL respectively, and then mixed in a volume ratio of 1:1. The resulting mixture was then mixed with a volume ratio of 1:1 and emulsified to prepare a bivalent porcine circovirus VLP vaccine.
[0096] Experimental example
[0097] This experimental example is an animal immune effect test of the porcine circovirus bivalent VLP vaccine prepared in Example 2: in a porcine circovirus-positive pig farm, sows were randomly selected for immunization, the immunization time was 30 days before the sows gave birth, the immunization dose was 1 mL / head, and 30 days after the sows gave birth, 6 piglets were randomly selected for blood extraction and serum separation.
[0098] The immune effect of porcine circovirus type 2 was determined by testing the antibody titer with a kit. The criteria were porcine circovirus type 2 antibody: S / P value ≥ 0.16 for positive, S / P value < 0.16 for negative. The results are as follows:
[0099] Table 1 Results of the verification of the immune effect of porcine circovirus type 2
[0100]
[0101] From the test results in Table 1, it can be seen that the maternal antibodies to PCV2 Cap protein in piglets are still positive after 30 days, which can protect piglets from infection with PCV2 virus.
[0102] The immune effect of porcine circovirus type 3 was also determined by testing the antibody titer using a kit. The criteria for porcine circovirus type 3 antibodies were: S / P value ≥ 0.15 for positive, and S / P value < 0.15 for negative. The results are as follows:
[0103] Table 2 Results of the verification of the immune effect of porcine circovirus type 3
[0104]
[0105] From the test results in Table 2, it can be seen that the maternal antibodies against PCV3 in piglets are positive after 30 days, indicating that the vaccine candidate of the present invention has a good immune effect.
[0106] In summary, both VLP antigens of the present invention show good immunogenicity, and the expression and purification methods can adapt to the needs of large-scale production. Currently, there are no commercialized porcine circovirus type 2 and type 3 bivalent vaccine products on the market, so the present invention has good application prospects.
[0107] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A porcine circovirus type 2 / type 3 virus-like particle, characterized in that: It includes porcine circovirus type 2 virus-like particles and porcine circovirus type 3 virus-like particles; the porcine circovirus type 2 virus-like particles include porcine circovirus type 2 Cap protein, and the porcine circovirus type 3 virus-like particles include porcine circovirus type 3 Cap protein; The nucleotide sequence of the porcine circovirus type 2 Cap protein gene is shown in SEQ ID NO.2, and the nucleotide sequence of the porcine circovirus type 3 Cap protein gene is shown in SEQ ID NO.
4.
2. The method for preparing porcine circovirus type 2 or type 3 virus-like particles according to claim 1, characterized in that: include: The nucleic acid molecule encoding the porcine circovirus type 2 Cap protein is connected to a shuttle plasmid, and then the obtained recombinant vector is transformed into a host competent cell to form a recombinant bacmid containing the nucleic acid molecule of claim 1, and then the recombinant bacmid is transfected into insect cells to obtain a recombinant cell; the recombinant cell is fermented, cultured, separated and purified to obtain porcine circovirus type 2 virus-like particles and porcine circovirus type 3 virus-like particles; The shuttle plasmids include pFastBac HTA, pFastBac HTB, pFastBac HTC, pFastBac 1 and pFastBac Dual; The insect cells include sf9 cells and High Five cells.
3. The method for preparing porcine circovirus type 2 or type 3 virus-like particles according to claim 2, characterized in that: The purification comprises: performing cation exchange chromatography on the cell-disrupted supernatant; The buffer used in the preparation of the cell lysis supernatant is: 20mM PB, 100mM NaCl, pH6.8; or the buffer is: 20mM PB, 10mM NaCl, pH6.8; The fillers of the cation exchange chromatography include SP LS HP and Capto S ImpAct fillers; The eluent of the cation exchange chromatography is: 20mM PB, 1M NaCl, pH=6.8; or the eluent is: 20mM PB, 200mM NaCl, pH=6.
8.
4. A porcine circovirus type 2 / 3 bivalent virus-like particle vaccine, characterized in that: It comprises the porcine circovirus type 2 virus-like particles and porcine circovirus type 3 virus-like particles described in claim 1.
5. The porcine circovirus type 2 / 3 bivalent virus-like particle vaccine according to claim 4, characterized in that: The concentration ratio of porcine circovirus type 2 virus-like particles to porcine circovirus type 3 virus-like particles in the porcine circovirus bivalent virus-like particle vaccine is 1:1 to 1:
2.
6. The porcine circovirus type 2 / 3 bivalent virus-like particle vaccine according to claim 5, characterized in that: The concentrations of the porcine circovirus type 2 virus-like particles and the porcine circovirus type 3 virus-like particles are both 60 μg / mL to 200 μg / mL.
7. The porcine circovirus type 2 / 3 bivalent virus-like particle vaccine according to claim 6, characterized in that: The porcine circovirus bivalent virus-like particle vaccine also contains a pharmaceutically acceptable carrier, diluent or excipient.
8. The porcine circovirus type 2 / 3 bivalent virus-like particle vaccine according to claim 7, characterized in that: The porcine circovirus bivalent virus-like particle vaccine includes an adjuvant; the adjuvant includes an oil phase adjuvant.
9. The porcine circovirus type 2 / 3 bivalent virus-like particle vaccine according to claim 8, characterized in that The volume ratio of the mixture of porcine circovirus type 2 virus-like particles and porcine circovirus type 3 virus-like particles in the porcine circovirus bivalent virus-like particle vaccine to the adjuvant is 9:1 to 1:1.
